American College of Cardiology Foundation. Published by Elsevier Inc.
Doi
Abstract
ObjectivesThe aim of the present study was to analyze whether beta3-adrenoceptors (β3-ARs) were effectively present and functional in the human internal mammary artery (IMA).BackgroundThe beta1- and beta2-adrenoceptors classically mediate the relaxant effects of catecholamines in the vessels. In vitro and in vivo studies performed in various animal species described vasodilating effects due to activation of a third beta-ARs subtype (β3).MethodsReverse transcription-polymerase chain reaction analysis, Western blot experiments, and pharmacological studies were carried out in human IMA samples harvested from 27 patients undergoing coronary bypass surgery.ResultsThe β3-ARs messenger ribonucleic acid and protein were detected in intact IMA, but were absent in endothelium-free samples. This finding was confirmed by immunohistochemical experiments. In organ baths, a β3-AR agonist, SR 58611A, induced an endothelium-dependent relaxation of phenylephrine-precontracted IMA rings. This vasodilation was not modified by β1/β2-AR antagonists, but was greatly altered in the presence of L-748,337, a selective human β3-AR antagonist. Moreover, the inhibition of nitric oxide (NO) synthases abolished the β3-adrenergic vasodilation, suggesting the involvement of a NO-signaling pathway.ConclusionsThose results demonstrated the presence of β3-ARs in the endothelial layer of human IMA. The present work highlights the role of β3-ARs in vasomotor control of IMA and opens new fields of investigation in coronary bypass graft management, heart failure, and hypertension
Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.